Serena Therapeutics

Serena Therapeutics is a biotechnology company dedicated to developing next-generation treatments for metastatic castration-resistant prostate cancer (mCRPC). The company specializes in targeting the N-terminal domain (NTD) of the androgen receptor, a region critical for the receptor's transcriptional activity but historically considered undruggable due to its intrinsically disordered structure. By developing small molecule inhibitors that bind to the NTD, Serena aims to overcome resistance mechanisms that affect current standard-of-care therapies targeting the ligand-binding domain. Founded as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA, the company leverages advanced structural biology and medicinal chemistry to advance its pipeline. Serena Therapeutics is positioned to address a significant unmet need for patients whose cancer has progressed despite existing hormonal treatments.